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Abstract
 
Transduction of Tat-tagged fusion proteins confirmed a hypothesis based on pharmacologic in-
hibitors (Fuortes, M., M. Melchior, H. Han, G.J. Lyon, and C. Nathan. 1999. 
 
J. Clin. Invest.
 
104:327–335) that proline-rich tyrosine kinase (Pyk2) plays a critical role in the activation of
adherent human neutrophils, and allowed an analysis of individual Pyk2 domains not possible
with chemical inhibitors. Acting as a dominant negative, the COOH terminus of Pyk2 fused to
a Tat peptide (Tat-CT), but not other regions of Pyk2, specifically inhibited the respiratory
burst of cells responding to tumor necrosis factor (TNF), 
 
Salmonella
 
, or 
 
Listeria
 
, while sparing
responses induced by phorbol ester. Tat-CT suppressed TNF-triggered cell spreading and the
phosphorylation of endogenous Pyk2 and the associated tyrosine kinase Syk without blocking
the ability of neutrophils to degranulate and kill bacteria. Thus, separate signals control the re-
spiratory burst and degranulation, and a normal rate of killing of some bacteria can be sustained
by granule products in conjunction with a minimal residual respiratory burst. Inhibition of se-
lect inflammatory functions without impairment of antibacterial activity may commend the
Pyk2 pathway as a potential target for antiinflammatory therapy.
Key words: neutrophil • Pyk2 • Syk • Tat • TNF
 
Introduction
 
An inherent dilemma of antiinflammatory therapy, the risk
of impairing host defense, is particularly problematic with
neutrophils. Adherence of neutrophils to endothelium,
their diapedesis from venules into tissues and their release
of peptides, proteases, and reactive oxygen intermediates
underlie both their killing of bacteria and their damage to
tissues. The histotoxic impact of neutrophils is prominent
in several inflammatory settings that are not thought to in-
volve bacterial infection, such as rheumatoid arthritis,
Crohn’s disease, and ischemia-reperfusion syndrome, or in
which neutrophil-mediated injury can occur at sites remote
from invading bacteria, as in the acute respiratory distress
and systemic inflammatory response syndromes. The stim-
uli that activate neutrophils in these settings are host-
derived mediators rather than bacteria themselves. Pharma-
cologic agents might be able to target some inflammatory
functions of neutrophils while sparing antimicrobial func-
tions if some signaling steps involved in the activation of
neutrophils by host-derived mediators were distinct from
steps involved in the ingestion and killing of bacteria.
Full activation of neutrophils by soluble host products re-
quires a binary signal. One part of the signal consists of inte-
grin ligation during adherence to extracellular matrix. Si-
multaneously, a factor such as TNF, lymphotoxin, C5a,
formylated peptides, macrophage inflammatory protein
 
(MIP)-1,
 
*
 
 CSF-G, or GM-CSF must engage its receptor(s)
on the neutrophil (1–4). TNF has been studied intensively
both with respect to the mechanisms by which it activates
adherent neutrophils (2, 5–15) and the benefit of its neutral-
ization in inflammatory disorders such as rheumatoid arthritis
(16), ankylosing spondylitis (17), and Crohn’s disease (18).
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6505; Fax: 212-746-8587; E-mail: cnathan@med.cornell.edu
 
*
 
Abbreviations used in this paper:
 
 GBM, Grb2 binding domain; KRPG,
Krebs Ringer phosphate with glucose; LAMP, lysosomal-associated
membrane protein; LDH, lactate dehydrogenase; LF, lactoferrin; MIP,
macrophage inflammatory protein; MPO, myeloperoxidase; phox, phago-
cyte oxidase; PI3K, phosphatidylinositol-3 kinase; Pyk2, proline-rich ty-
rosine kinase.T
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Proline-rich tyrosine kinase (Pyk2; reference 19), also
called related adhesion focal tyrosine kinase (20), cell adhe-
sion kinase-
 
  
 
(21), calcium-dependent tyrosine kinase (22),
and focal adhesion kinase 2 (23), is a nonreceptor kinase
expressed abundantly in hematopoietic cells. Pyk2 is distin-
guished by a lack of SH2 and SH3 domains. Pyk2’s kinase
domain is flanked instead by large 
 
N
 
- and COOH-terminal
extensions that are involved in binding diverse kinases and
substrates in various cells (24–26). Previous studies identi-
fied Pyk2 in human neutrophils, localized it to focal adhe-
sions and podosomes, and demonstrated its tyrosine phos-
phorylation, activation, and association with paxillin during
stimulation of adherent neutrophils by TNF (27, 28). One
tyrosine kinase inhibitor of 51 that was tested, tyrphostin
A9, blocked both the activation of TNF-treated neutro-
phils and the tyrosine phosphorylation of Pyk2 (27). How-
ever, it was not established whether tyrphostin A9 targeted
Pyk2 directly. Tyrphostin A9 may instead have inhibited
another kinase for which Pyk2 was a target. Tyrphostin A9
inhibits the platelet-derived growth factor receptor (29)
and as with most chemical inhibitors, the full range of its
targets is unknown.
In the analysis of intracellular signaling, limited availabil-
ity, specificity, or knowledge of the specificity of chemical
inhibitors has directed attention to interventions based on
DNA, RNA, or peptide sequences. However, the options
for applying such approaches to neutrophils have been
more restricted than with most other cell types. Gene dis-
ruption by homologous recombination has aided the study
of neutrophils in the mouse, but the relevance for human
neutrophils is uncertain. Although the respiratory burst of
mouse neutrophils in response to phorbol esters is of the
same magnitude as that of human neutrophils, the response
of mouse neutrophils to soluble, physiologic agonists like
TNF is 10-fold lower than for their human counterparts
(15, 30) and in some laboratories is rarely demonstrable
(unpublished data and P. Detmers, personal communica-
tion). Such species differences underscore the importance
of studies in human neutrophils themselves. Transfection of
cDNAs, antisense constructs, and inhibitory RNAs is not
useful in primary neutrophils, because neutrophil activation
depends on posttranslational modifications of preformed
proteins whose half-life exceeds the lifetime of the cells un-
der the conditions of study. Myeloid cell lines can be trans-
fected with difficulty (31), but do not undergo a TNF-
induced respiratory burst even after differentiative agents
drive a minority of the population toward maturity.
With other approaches so constrained, protein transduc-
tion holds special interest for the analysis of signaling in pri-
mary neutrophils. Loading procedures such as osmotic
shock, scraping, streptolysin O permeabilization, and elec-
troporation tend to activate or damage neutrophils as evi-
denced when subsequent studies span several hours.
Recently, transduction based on membrane-permeant se-
quences in the HIV 
 
tat
 
 gene product (32) has been de-
scribed in neutrophils (33, 34) and eosinophils (35–38), but
questions remain that appear to have restricted the use of
this approach.
In this work, we studied the transduction of Tat-tagged,
Pyk2-derived polypeptides into human neutrophils. This
allowed both a comparison to and an extension of earlier
work with kinase inhibitors (27). The approaches used for
purification of the fusion proteins were critical. The vast
majority of Tat-tagged proteins taken up appeared to reside
in endosomes. However, enough reached the cytosol to
demonstrate that the carboxyl terminus of Pyk2 is critical
for TNF or bacteria to trigger the respiratory burst. At the
same time, the Pyk2 carboxyl terminus does not appear to
control degranulation. Finally, it appears that the Pyk2
pathway can be targeted without impairing bacterial killing
in vitro.
 
Materials and Methods
 
Cells.
 
Neutrophils were isolated to 
 
 
 
95% purity from 10
U/ml heparinized blood of normal donors using Poly-
morphprep™ (Axis-Shield PoC) according to the manufacturer’s
instructions. Contaminating erythrocytes were lysed by hypo-
tonic shock for 45 s with 0.2% saline. Neutrophils were resus-
pended in Krebs Ringer phosphate with glucose (KRPG) formu-
lated as previously described (39).
 
Tat Fusion Proteins.
 
The vector pTatHA (32) was provided
by S. Dowdy, Washington University, St. Louis, MO. Domains
of Pyk2 were amplified from pRK5-Pyk2 (provided by J.
Schlessinger, New York University, New York, NY) as a tem-
plate using the following primer sets: autophosphorylation site
(AP, nt 1102–1557): GTGAATTCGGATGGTGAGAAGCG-
GAACAGC and CTGAATTCTTCTTGTTCCGCTCCAGG-
TAGT; phosphatidyl inositol 3
 
  
 
phosphate (PI3) kinase binding
domain (PBM, nt 1741–2099): GTGAATTCGAAAGCCTCT-
GTGACTCGT and CAGAATTCGTTCGGTAGCGAGCAT-
TCCT; Grb2 binding domain (GBM, nt 2617–2986): GTG-
AATTCAGACCGGACCGATGACCTG and GTGAATTC-
TCCACAGCGTCGAGCAGGTT; and proline-rich region
(PR, nt 2041–3030): CAGAATTCGGACGTTTATCAGA-
TGGAGAA and GCGAATTCTCACTCTGCAGGTGGGTG.
Full-length Rac2 was amplified using pCR-rac2 wt (provided by
D. Ambruso, University of Colorado, Denver, CO) as template
with primers GTGAATTCGATGCAGGCCATCAAG and
CTGAATTCCTAGAGGAGGCTGCAG. PCR products and
the pTatHA vector were digested with EcoRI, gel purified, li-
gated (Rapid Ligation Kit; Roche), and used for the transforma-
tion of 
 
Escherichia coli
 
 XL10 (Stratagene). Transformed 
 
E. coli
 
BL21 DE 3 (Novagene) served as host for recombinant protein
expression. BL21 cells were resuspended in buffer Z (8 M urea,
20 mM Hepes, 100 mM NaCl, pH 8.0), sonicated, and centri-
fuged at 17,500 
 
g 
 
for
 
 
 
20 min. The supernatant was loaded on a
Ni-NTA column (QIAGEN), which was washed with 50 col-
umn volumes of buffer Z to remove contaminating proteins, fol-
lowed by 100 column volumes of 60% isopropanol in 20 mM
Hepes and 50 column volumes of 20 mM Hepes to remove en-
dotoxin (40). Residual LPS was measured by the chromogenic
 
Limulus
 
 amebocyte assay (Biowhittaker). As previously reported
(2), LPS at concentrations ranging from 10 to 100 ng/ml had no
effect on the cell functions we analyzed either when tested alone
or in the presence of TNF, nor did LPS affect results seen in the
additional presence of Tat constructs (unpublished data). Recom-
binant Tat fusion proteins with NH
 
2
 
-terminal hexa-His tags were
eluted with an imidazole gradient in buffer Z. Fractions contain-T
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ing 
 
 
 
95% pure recombinant proteins were pooled, diluted 10-
fold in 20 mM Hepes, pH 8.0, filtered six times on YM ultrafil-
tration discs (Millipore) using Amicon Stirred Cells (model 8050)
to remove urea and imidazole, and stored at 4
 
 
 
C until use. Pro-
tein aggregates forming during storage were removed by ultra-
centrifugation at 100,000 
 
g 
 
at 4
 
 
 
C for 15 min immediately before
each experiment and protein concentration was measured by Dc
protein assay (Bio-Rad Laboratories).
 
Flow Cytometry and Confocal Microscopy.
 
Tat fusion proteins
were labeled with Alexa fluor 488 (Molecular Probes) according
to the manufacturer’s instructions. Neutrophils were incubated
with labeled proteins for the indicated times at 37
 
 
 
C in 5-ml
polypropylene round-bottom tubes (Falcon), precoated with FBS
(Hyclone Laboratories), washed three times with cold washing
buffer (0.1% Tween-20 in PBS), fixed with 2% paraformaldehyde
in PBS, washed four times with cold washing buffer, resuspended
in 2 ml 1% BSA in PBS, and analyzed on a FACScan™ (Becton
Dickinson). Aliquots of the same cell suspensions were permeabi-
lized with 3.3% paraformaldehyde, 0.05% glutaraldehyde, and
0.25 mg/ml saponin in PBS for 4 min at room temperature. The
reactions were stopped with the same volume of 20 mM glycine
buffer. The cells were washed three times with PBS, incubated in
25% goat serum in PBS at room temperature for 30 min, in-
cubated with anti–lysosomal-associated membrane protein
(LAMP)-1 mAb (provided by R. Silverstein, Weill Cornell Med-
ical College, New York, NY) at 4
 
 
 
C overnight, washed, incu-
bated with goat anti–mouse Ab conjugated with Alexa fluor 546
at room temperature for 30 min, and observed by confocal mi-
croscopy (LSM 510; Carl Zeiss MicroImaging, Inc.).
 
H
 
2
 
O
 
2
 
 Release and Degranulation.
 
The respiratory burst was
measured as previously described (39). In brief, 96-well flat-bot-
tomed plates (Primaria; Falcon) were coated with 25 
 
 
 
l/well FBS
in 5% CO
 
2 
 
at 37
 
 
 
C for at least 1 h and washed three times with
0.9% saline. 1.5 
 
  
 
10
 
4 
 
neutrophils were added to triplicate wells
containing 100 
 
 
 
l reaction mixture (2.4 nmol scopoletin, 0.5 
 
 
 
g
horseradish peroxidase, and 1 mM NaN
 
3
 
) and either buffer con-
trol, TNF (Genentech, Inc. or PreproTech) or PMA, each at 100
ng/ml. The reduction of scopoletin by H
 
2
 
O
 
2 
 
was recorded every
15 min for 2 h on a plate-reading fluorometer and the amount of
H
 
2
 
O
 
2 
 
released was calculated as previously described (39). The
supernate from the H
 
2
 
O
 
2 
 
release assay with 1.0 
 
  
 
10
 
5 
 
neutrophils
was used to measure degranulation using lactoferrin (LF) and my-
eloperoxidase (MPO) ELISA kits (Oxis International, Inc.), or to
measure spontaneous cell death using Cytotoxicity Detection Kit
(Roche). The total cell content of LF, MPO, and lactate dehy-
drogenase (LDH) was determined after lysing cells with 1% Tri-
ton X-100. The percent of cell death was determined by dividing
the amount of LDH released spontaneously or in response to test
agents by the amount of LDH released in response to detergent.
Similarly, the percent of degranulation was determined by divid-
ing the amount of LF or MPO released spontaneously or in re-
sponse to test agents by the amount released in response to deter-
gent, correcting for the amount of LF or MPO that may have
been released in association with cell death.
 
Bacterial Killing.
 
Neutrophils were preincubated with or
without 500 nM recombinant Tat fusion protein for 30 min at
37
 
 
 
C and then exposed to 10% autologous serum-opsonized 
 
Sal-
monella typhimurium
 
 (American Type Culture Collection [ATCC]
14028s) or 
 
Listeria monocytogenes
 
 (ATCC 15323) at a multiplicity
of infection of 0.5 bacteria per neutrophil. Neutrophils were
lysed at the indicated times with 1% sodium deoxycholate for as-
says with 
 
Salmonella
 
 or 1% Triton X-100 for assays with 
 
Listeria
 
.
Bacteria were grown in Luria-Bertani medium containing 10%
 
Alamar Blue™ (Trek Diagnostic Systems, Inc.). The time for
half-maximal growth was monitored and converted to CFUs us-
ing a standard curve as previously described (41).
 
Immunoprecipitation and Immunoblot.
 
15 
 
  
 
10
 
6 
 
neutrophils in
KRPG were plated in 10-cm diameter dishes (Primaria) that had
been precoated with FBS. After 15 min at 37
 
 
 
C, the cells were
stimulated with 100 ng/ml TNF. When the cells were fully
spread (40–60 min), they were treated with 5 mM diisopropyl-
fluorophosphate to inhibit serine proteases and lysed with either
125 
 
 
 
l SDS lysis buffer (10 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 1% SDS, 1 mM PMSF, 1 mM Na pyrophosphate, 1 mM
NaF, 1 mM vanadate, 5 
 
 
 
g/ml each of aprotinin, leupeptin, chy-
mostatin, and pepstatin A) for Western blot or with 200 
 
 
 
l non-
denaturing modified RIPA buffer (10 mM Tris-HCl, pH 7.6,
150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 1 mM Na py-
rophosphate, 1 mM NaF, 1 mM vanadate, 5 
 
 
 
g/ml each of apro-
tinin, leupeptin, chymostatin, and pepstatin A) for immu-
noprecipitation. Cell lysates were separated by SDS-PAGE
and transferred electrophoretically to nitrocellulose membranes
(Schleicher & Schuell). The membranes were incubated with 5%
milk in TBST (1 M Tris-HCl, pH 7.5, 9% NaCl, 0.1% Tween-
20) for 1 h at 37
 
 
 
C and then overnight at 4
 
 
 
C with antiphospho-
specific Pyk2 Abs (Biosource International), anti-Pyk2 Ab (Upstate
Biotechnology), or anti-Syk Ab (Transduction Laboratories).
Membranes were washed with TBST and incubated with sec-
ondary Ab conjugated with horseradish peroxidase in 5% milk in
TBST for 1 h at 37
 
 
 
C. After additional washing with TBST,
bound antibody was detected by enhanced chemiluminescence
(Pierce Chemical Co.).
 
Results
 
Domains of Pyk2 Expressed as Tat Fusion Proteins.
 
Four
recombinant Tat fusion proteins were designed based on
homology to FAK and studies of Pyk2 in other cells (Fig.
1; reference 26). In Tat-AP, Tat peptide was fused to
Pyk2’s autophosphorylation domain (amino acid residues
365–518, including Y402, the residue that undergoes au-
tophosphorylation). The fusion in Tat-PBM was to
Pyk2’s phosphatidylinositol-3 kinase (PI3K) binding motif
(amino acid residues 581–700, including a sequence,
YTLM, thought to be involved in binding the p85 SH2
domain of P13K) and in Tat-GBM was to the Grb2-bind-
ing motif (amino acids 873–995, including Y881). In Tat-
CT, Tat peptide was fused to the NH
 
2 
 
terminus of Pyk2’s
proline-rich COOH-terminal domain (amino acid resi-
Figure 1. Schematic representation of the Pyk2 regions expressed as
Tat fusion proteins. Pro denotes the proline-rich regions critical for some
of the protein–protein interactions associated with the COOH terminus
of Pyk2. The ball and stick represent the Tat peptide, hexahistidine, and
hemagglutinin tag. Amino acid residue numbers are shown in parentheses.T
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dues 680–1009). LPS was scrubbed to 
 
 
 
5 ng/ml at 500
nM used after purification of the recombinant proteins
from 
 
E. coli.
Uptake of Tat Fusion Proteins by Human Neutrophils.
 
Fluorescently labeled, Tat-tagged proteins were incubated
with neutrophils and uptake was assessed by flow cytome-
try. Uptake varied strikingly with the method used to de-
salt the purified fusion proteins. Purification by ion ex-
change followed by gel permeation chromatography led to
maximal uptake in 30 min, but factors eluting from the
ion exchange column were toxic to the cells (not de-
picted). In contrast, preparations desalted by membrane
filtration were nontoxic. These preparations were subject
to increasing uptake with time over at least 120 min at
37
 
 
 
C, as shown for Tat-AP in Fig. 2 A and for Tat-CT in
Fig. 2, B and C. The apparent extent of uptake was mark-
edly augmented by chloroquine (Fig. 2 C), suggesting that
lysosomal degradation may normally limit the accumula-
tion and intracellular retention of the fluorescent marker.
There was no detectable uptake at 4
 
 
 
C over the same time
periods (not depicted). No saturation of uptake was
achieved at concentrations up to 1 
 
 
 
M (Fig. 2, D and E).
Fluorescence was almost entirely intracellular, as judged by
the inability of trypan blue to quench it. As a control, try-
pan blue did quench fluorescence imparted by fluorescent
antibody directed to a cell surface antigen, CD11c (not de-
picted). Optimal protein transduction required both Ca
 
2
 
 
 
and Mg
 
2
 
  
 
and was insensitive to pH over the range of 6.8–
7.4 (not depicted). All additional work involved fusion
proteins desalted by membrane filtration and a standard
loading time of 30 min, because this sufficed to label
 
 
 
90% of the cells.
 
Intracellular Distribution of Tat Fusion Proteins.
 
Tat fu-
sion proteins have been shown to enter polymorphonu-
clear leukocytes (34, 38), but it has not been assessed
whether uptake is chiefly into the cytosol, as required to
inhibit the signaling molecules targeted; into the nucleus,
as expected from Tat’s nuclear localization signal and as
observed in several other types of cells (42–44); or into
the endosome-lysosome system via absorptive endocytosis
as also observed in various cells (43, 44). Confocal micros-
copy of neutrophils exposed to Tat-AP and Tat-CT con-
firmed that all detectable staining was intracellular (Fig. 3,
rows 1–3). The Tat fusion protein was excluded from
rather than concentrated in the neutrophil nucleus (not
depicted). Cytoplasmic staining was consistently visible al-
though difficult to demonstrate in photomicrographs.
However, the majority of staining was distributed in
punctate collections throughout the cytoplasm that were
almost entirely nonoverlapping with LAMP-1 (Fig. 3,
rows 2 and 3). The variation in staining patterns illustrated
in Fig. 3, rows 2 and 3, was not an intrinsic property of
the Tat peptide studied. Both Tat-AP and Tat-Ct most
often gave the pattern illustrated in row 2. Pretreatment
of neutrophils with chloroquine before protein transduc-
tion led to dramatic intensification of both cytoplasmic
and punctate staining (Fig. 3, row 1). Chloroquine ele-
vates lysosomal pH (45) and blocks degradation of Tat in
HeLa cells (42). The fluor used in these experiments is in-
sensitive to pH over the range pH 4–10. Thus, a change
in fluorescence efficiency does not account for the impact
of chloroquine on signal intensity. A plausible interpreta-
tion of the findings in Figs. 2 C and 3 is that Tat con-
structs were taken up and largely retained in endosomes.
Some passed into lysosomes, where degradation may have
led to rapid removal of the fluor. With inhibition of lyso-
somal degradation, intact Tat fusion protein may have ac-
cumulated in lysosomes and endosomes. Biochemical evi-
dence supported the conclusion that most of the Tat
fusion proteins accumulating in neutrophils were in a
degradative compartment. Although reagent Tat-CT was
readily immunoprecipitated, no intact Tat-CT could be
Figure 2. Uptake of Tat fu-
sion proteins by human PMNs,
FACS® analysis. Flow cytometric
analysis of the uptake of Tat fu-
sion proteins by neutrophils. The
cells were incubated with labeled
Tat-AP (A and D) or Tat-CT
(B, C, and E), either with 1  M
Tat construct for the indicated
time at 37 C (A, B, and C), or
for 60 min at 37 C with the in-
dicated concentration of Tat
construct (D and E). In C, cells
were also preincubated with 100
 M chloroquine for 30 min at
37 C.T
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visualized on anti-hexahistidine immunoblots of immu-
noprecipitated lysates of neutrophils that had been incu-
bated with Tat-CT. Instead, immunoblot displayed nu-
merous His-tagged peptides of lower 
 
M
 
r 
 
(unpublished
data). In summary, large amounts of Tat proteins entered
neutrophils, but the vast majority appeared to be degraded
in the endosomal compartment with only traces reaching
the cytosol.
Figure 3. Distribution of Tat fusion proteins within human PMNs, confocal microscopy. Neutrophils were incubated with 1  M fluorescent Tat-CT
(rows 1 and 3), Tat-AP (row 2), or no protein (row 4), and stained for the lysosomal marker LAMP-1 (rows 2 and 3). Neutrophils were treated without
(row 1, left) or with 100  M chloroquine (row 1, right, and rows 2–4) along with the Tat fusion protein for 1 h at 37 C and then permeabilized and
stained. Differential interference contrast microscopy (DIC) demonstrates the presence of cells.  800 for row 1 and  2,000 for rows 2–4.T
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Dominant Negative Pyk2 Constructs Inhibit the Respiratory
Burst Triggered by TNF in Adherent Neutrophils.
 
Tat-CT
selectively inhibited the TNF-triggered respiratory burst in
a concentration-dependent manner (Fig. 4 A). Despite
variation associated with the use of 18 different blood do-
nors and 5 independently prepared batches of recombinant
protein, 70–90% inhibition was consistently achieved by
500 nM Tat-CT and 50% inhibition required a mean of
250 nM (Fig. 4 B). Tat-CT had no effect on its own nor
on the respiratory burst triggered by PMA. PMA was used
as a control stimulus because it triggers the same spectrum
of responses in adherent neutrophils as TNF, but bypasses
surface receptors to act directly on protein kinase C. Spar-
ing of the PMA-induced response indicated that the Tat
transduction system was not toxic for neutrophils and did
not interfere with the assay.
 
Results of multiple experiments are summarized in Fig. 4
B. No constructs inhibited responses to PMA. With respect
to responses to TNF, Tat-GBM afforded a mean of 38%
inhibition, Tat-AP 23% inhibition, and Tat-PBM 16% in-
hibition when each was tested at 500 nM. The differences
in the effect of individual domains of Pyk2 were not due to
differences in uptake (Fig. 2). Another specificity control
was provided by Tat-Rac2. Rac2 is a small GTP binding
protein that constitutes a subunit of the phagocyte oxidase
in human neutrophils (46). In three experiments, Tat-Rac2
afforded a mean of 
 
 
 
15% inhibition of the respiratory burst
induced by TNF and 
 
 
 
4% of that induced by PMA (not
depicted). However, the rapid aggregation of Tat-Rac2
upon storage required that a fresh purification be per-
formed for every experiment. In subsequent experiments,
Tat-CT was used as a test agent and ovalbumin as a control
for added protein.
 
Inhibition of TNF-triggered Cell Spreading by Tat-CT.
 
The respiratory burst of adherent neutrophils triggered by
soluble, physiologic agents depends on rearrangement of
the actin-based cytoskeleton and cell spreading. Rear-
rangement of actin bundles from a dense, subcortical
meshwork to interconnected focal adhesions and podo-
somes might be necessary to permit vesicular and cytoplas-
mic components of the phagocyte oxidase complex to be
mobilized together to the plasma membrane. To deter-
mine whether Pyk2 helps mediate cytoskeletal rearrange-
ment, we treated neutrophils with Tat-CT or buffer and
then did or did not activate them with PMA or TNF. As
shown in Fig. 5, neutrophils adhered to serum-coated glass
but did not spread unless activated. Tat-CT failed to im-
pede cell spreading induced by PMA. Cells preincubated
with Tat-CT and then exposed to TNF began to spread
but were arrested before they had extended filopodia and
completely flattened (Fig. 5). These findings suggested that
Tat-CT did not interfere with the ability of TNF to bind
to its receptors nor with the earliest steps in signal trans-
duction. Instead, Tat-CT blocked an intermediate stage in
the response to TNF.
 
Impact of Tat-CT on TNF-triggered Degranulation.
 
Any
stimulus that triggers the respiratory burst in neutrophils
generally triggers degranulation and vice versa. With ex-
tensive overlap in the signaling pathways inducing both
processes, it is unclear whether there is any respect in
which they are regulated differentially. To test the role of
the carboxyl terminus of Pyk2 in degranulation, we did or
did not activate neutrophils with TNF after preincubation
with 500 nM Ova or Tat-CT for 30 min, harvested the su-
pernatant at 60–90 min, and measured the concentration of
the specific granule protein LF and of the azurophil granule
protein MPO, correcting for cell death as reflected by re-
lease of the cytosolic enzyme LDH. Tat-CT had no effect
on TNF-induced specific release of LF and MPO (Fig. 6).
In the same experiments, Tat-CT blocked the TNF-induced
respiratory burst by 
 
 
 
80%.
 
Inhibition of TNF-dependent Tyrosine Phosphorylation of En-
dogenous Pyk2 in the Presence of Tat-CT.
 
To explore the
biochemical basis for the inhibition of TNF-induced re-
Figure 4. Effect of Pyk2 domains on the respiratory burst of adherent
neutrophils. (A) Concentration-dependent effect of Tat-CT. Neutrophils
were preincubated with the indicated concentrations of Tat-CT at 37 C
for 30 min before stimulation with 100 ng/ml TNF, 100 ng/ml PMA, or
an equivalent volume of KRPG buffer as a control. H2O2 release was
measured at 15-min intervals. Results are displayed for 75 min and ex-
pressed as means   SEM for triplicates in one representative experiment.
(B) Summary of experiments with Tat-CT and other Pyk2 constructs.
Results are means   SEM for results at 100–120 min from the number of
experiments with different blood donors shown in parentheses, each in
triplicate. Percent inhibition was calculated in comparison to results for
TNF without Tat fusion proteins in the same experiments.T
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sponses by Tat-CT, we first examined the most abundant
tyrosine phosphoproteins by immunoblots after one-
dimensional SDS-PAGE. As shown in Fig. 7 A, there was
no gross alteration in the pattern of TNF-induced protein
tyrosine phosphorylation in adherent neutrophils in the
presence of Tat-CT, although the intensity of several bands
was slightly diminished. Next, we immunoprecipitated
Pyk2 and investigated the effect of Tat-CT on the phos-
phorylation of tyrosine residues 402, 570, and 881, which
have been shown to play important roles in Pyk2’s func-
tions in other cell types. TNF-induced phosphorylation of
all three tyrosines was inhibited in the presence of Tat-CT
(Fig. 7 B). Thus, Tat-CT acted as a dominant negative in
that it blocked the tyrosine phosphorylation of endogenous
Pyk2. Because the tyrosine phosphorylation of residue 402
is essential for Pyk2’s tyrosine kinase activity (26), it can be
presumed that Tat-CT also blocked the enzyme activity of
Pyk2. These findings implied that the COOH terminus of
Pyk2 is involved in protein–protein interactions that are
necessary for the activation of Pyk2.
 
Inhibition of TNF-dependent Association of Pyk2 and Syk by
Tat-CT.
 
Syk, like Pyk2, is a tyrosine kinase that under-
goes activation in TNF-treated human neutrophils (47). In
earlier work, wortmannin, a PI3K inhibitor, appeared to
block the TNF-induced tyrosine phosphorylation of only
one protein in adherent neutrophils besides Pyk2, namely
an unidentified 80-kD protein whose Mr matched that of
Syk (27). In mouse neutrophils, Syk associates with Pyk2
and is essential for the cells to respond to TNF, fMLF,
MIP-2, and LPS (48). In our experiments, Pyk2 and Syk
could indeed be coimmunoprecipitated from human neu-
trophils, but only after the cells were activated with TNF
(Fig. 8 A). Wortmannin inhibited the TNF-induced ty-
rosine phosphorylation not only of Pyk2 (27) but also of
Syk (Fig. 8 B). Finally, TNF-induced tyrosine phosphory-
lation of Syk was inhibited by Tat-CT (Fig. 8 C).
Figure 5. Inhibition of TNF-
triggered neutrophil spreading
by Tat-CT. Neutrophils were
plated on FBS-coated glass cov-
erslips and preincubated or not
with 500 nM Tat-CT at 37 C
for 30 min before stimulation
with 100 ng/ml TNF, 100 ng/
ml PMA, or an equal volume of
KRPG (Cont.), and fixed and
photographed with phase-con-
trast microscope.  1,000.T
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The Effect of Tat-CT on Bacteria-triggered Respiratory Burst
and Killing. Neutrophils underwent a robust respiratory
burst upon encountering S. typhimurium (ATCC 14028s; a
Gram-negative bacterium) and L. monocytogenes (ATCC
15323; a Gram-positive bacterium) that had been op-
sonized with autologous serum. Tat-CT inhibited the re-
spiratory burst triggered by each pathogen by a mean of
81% for Salmonella and 72% for Listeria (Fig. 9 A). How-
ever, the ability of neutrophils to kill these organisms was
unaffected by Tat-CT (Fig. 9 B).
Other Approaches to Protein Transduction. Transducing
peptides based on the homeodomain of Drosophila antenna-
pedia were effective in epithelial cells but were not detect-
ably taken up by human neutrophils (unpublished data, and
D. Thomas, personal communication). A peptide carrier
based on the signal sequence of the  3 integrin (49) was re-
ported to be effective in myeloid cell lines (49, 50). The
synthetic carrier (VTVLALGALAGVGVG) was coupled to
biotin and attached via its COOH terminus to the Pyk2
autophosphorylation site SIESDIYAEIPDET (residues
396–409). Neutrophils incubated with this peptide at 100
 M showed intense cytoplasmic staining. The same cargo-
carrier conjugate lacking biotin selectively blocked cell
spreading and the respiratory burst triggered by TNF and
formyl peptide, but not PMA. There was no inhibition by
a control peptide whose cargo sequence (underlined) was
scrambled (VTVLALGALAGVGVGATYEPSDISEIEID;
unpublished data and R. Webber, personal communica-
tion). These results were dependent on the protocol used
to purify the peptides and the factors responsible for pro-
ducing consistently effective lots eluded identification.
Thus, Tat-based transduction was the only approach that
worked consistently with human neutrophils.
Discussion
These experiments appear to have afforded the first op-
portunity to compare Tat-based protein transduction with
the use of a relatively specific pharmacologic inhibitor (27)
for the study of signaling in neutrophils. That these two ap-
proaches gave consistent results helps to validate Tat-based
transduction as a method of choice and increases confi-
dence in additional conclusions regarding the role of spe-
cific protein domains that can only be addressed at pres-
ent through protein transduction. Thus, the transduced
COOH terminus of Pyk2 reproduced the known actions
of tyrphostin A9 on neutrophils, blocking the TNF-
induced tyrosine phosphorylation of Pyk2 and Syk, the re-
lease of hydrogen peroxide, and the spreading of the cells,
Figure 6. Effect of Tat-CT on TNF-triggered neutrophil degranula-
tion. Neutrophils were incubated as indicated (test proteins were added at
500 nM) and their supernate was assayed for the presence of lactoferrin
(LF) as a measure of specific granule release and myeloperoxidase (MPO)
for azurophil granule release. LDH was measured as an indicator of spon-
taneous cell lysis. Specific LF (A) and MPO (B) release (corrected for cell
lysis) are shown normalized to that seen with TNF alone in the absence of
ovalbumin (ova) or Tat-CT. TNF alone led to the specific release of an
average of 67 and 27% of total detergent-releasable LF and MPO content
of the cells, respectively, over and above the mean 5% release that could
be attributed to cell death. Results are the mean   SEM in three inde-
pendent experiments for LF release and two for MPO release.
Figure 7. Inhibition of TNF-induced phosphorylation
of endogenous Pyk2 by Tat-CT. Neutrophils were prein-
cubated with Tat-CT or ovalbumin (ova; each 500 nM) at
37 C for 30 min and stimulated with TNF (T) or buffer
alone as a control (C). Total cell lysates were separated by
SDS-PAGE and western-blotted (WB) with (A) antiphos-
photyrosine Ab or (B) Abs specific for individual phospho-
tyrosine (PY) residues of Pyk2. One membrane was
stripped and reprobed with anti-Pyk2 Ab, demonstrating
equal loading of the lanes.T
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while sparing PMA-induced responses, TNF-triggered de-
granulation, and bactericidal activity. Additional evidence
for the validity of the Tat-based technique was provided by
the specificity and selectivity of effects achieved with Tat-
tagged constructs that incorporated other domains of Pyk2
or introduced a different protein, Rac2. By blocking ty-
rosine phosphorylation of endogenous Pyk2, the Tat-
tagged Pyk2 COOH terminus acted as a dominant nega-
tive. Tat constructs afforded gain-of-function phenotypes
in the two earlier reports with neutrophils (33, 34), illus-
trating the versatility of the approach.
Several protein transduction domains can confer the
ability to carry attached molecules across biological mem-
branes. The Tat protein from HIV-1, antennapaedia from
Drosophila, the signal sequence from the  3 integrin and
VP22 from HSV-1 have all been effective in some cells.
Of the first three, only Tat was successful with neutro-
phils. The factors are unknown that confer a wider cell
type range on Tat compared with other protein transduc-
tion domains. Nontoxicity of Tat constructs and consis-
tency of their effects depended on how the proteins were
purified. The bacterial expression system introduced LPS
contamination. Not all constructs were stable enough for
routine use. Thus, Tat-based transduction remains experi-
mentally demanding.
Most applications of Tat-based transduction require and
assume cytosolic localization. However, in work involv-
ing neutrophils or eosinophils, a predominant cytosolic
localization for Tat-tagged proteins has apparently been
documented in only one instance (34). In this study, the
predominant localization of the Tat constructs appeared
to be endosomal and the vast majority of the Tat con-
struct taken up was rapidly degraded. Nonetheless, by
confocal microscopy a very small fraction appeared to be
localized in the cytosol. Tat constructs are deliberately de-
natured to foster their uptake (32). To function as a dom-
inant negative, cytosolic Tat-CT presumably underwent
sufficient renaturation to compete with endogenous Pyk2
for protein–protein interactions. The concentration of ex-
tracellular Tat-CT affording 50% inhibition was 250 nM.
Figure 8. TNF-induced association of Pyk2 and Syk,
and the inhibition of tyrosine phosphorylation of Syk by
wortmannin and Tat-CT. (A) Pyk2 was immunoprecipi-
tated (IP) from neutrophils stimulated with TNF (T) or
treated with buffer alone as a control (C) and Western
blotted (WB) for Syk. (B) Syk was immunoprecipitated
from neutrophils after preincubation with or without TNF
(T) and/or 10 nM wortmannin and Western blotted for
phosphotyrosine (PY; top) or Syk (bottom). (C) Syk was
immunoprecipitated from neutrophils after preincubation
with or without TNF (T) and/or with Tat-CT or ovalbu-
min (ova; each 500 nM) at 37 C for 30 min and probed
with antiphosphotyrosine Ab (PY) or anti-Syk.
Figure 9. Effect of Tat-CT on interac-
tion of neutrophils with bacteria. (A) Impact
of Tat-CT or ovalbumin (ova; each 500
nM, 30 min preincubation) on the respira-
tory burst triggered by S. typhimurium or L.
monocytogenes, measured at 150 min. Results
are means   SEM for triplicates in a repre-
sentative experiment of two performed. (B)
Survival of bacteria in culture only (open
symbols) or in culture with neutrophils
(closed symbols). Survival of bacteria in the
presence of Ova (  and  ) or Tat-CT ( 
and  ) are shown in CFU/ml. Results are
means   SEM for triplicates in a representa-
tive experiment of three performed. Some
of the error bars fall within the symbols.T
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The concentration that was both cytosolic and renatured
is unknown.
The assignment of critical functions to the COOH ter-
minus of Pyk2 in neutrophils echoes the dominant negative
effect of electroporating the Pyk2 COOH terminus into
human monocytes to inhibit their spreading and motility
(51). The COOH terminus of Pyk2 is a versatile partner
for protein interactions in other cell types, for example
with p130 Cas (52), Grb2 (52), Hic-5 (53), and Pap  / 
(54). Immunoprecipitation of Pyk2 from neutrophils did
not bring down p130 Cas or Grb2 (not depicted). Investi-
gation is underway into the possible expression in neutro-
phils of Hic-5 and Pap  / .
Among the proteins reported to interact with Pyk2, Syk
is of particular interest because it was activated by TNF in
adherent human neutrophils (47) and was essential for ad-
herent mouse neutrophils to undergo activation in response
to TNF, fMLF, MIP-2, and LPS (48). Syk was constitu-
tively associated with  2 integrins in the myeloid cell line
HL-60, where its activation required cell spreading (55).
Because Pyk2 localized to focal adhesions and podosomes
(27), of which  2 integrins form the core, Pyk2 might acti-
vate Syk directly or indirectly in focal adhesions and podo-
somes. Activated Syk phosphorylated the focal adhesion
protein paxillin (56). Pharmacologic inhibition of Syk2
blocked tyrosine phosphorylation of Pyk2 (28). In this
study, TNF triggered the association of Pyk2 and Syk, and
inhibition of Pyk2 blocked the tyrosine phosphorylation of
Syk. TNF also triggered the binding of PI3K to TNF re-
ceptors and activation of PI3K in adherent human neutro-
phils (57). In this study, inhibition of PI3K blocked the ty-
rosine phosphorylation of both Pyk2 and Syk. Thus, in
response to TNF, Pyk2 and Syk both appear to control
each other’s activation, and PI3K appears to control the ac-
tivation of both of them.
Despite the close interactions among these three en-
zymes, the consequences of inhibiting or deleting PI3K,
Syk, and Pyk2 are not the same, either in isolated neutro-
phils or in the whole organism. Wortmannin-treated,
TNF-stimulated neutrophils adhered but did not spread at
all (27). In the presence of tyrphostin A9, TNF-stimulated
neutrophils began to spread and succeeded in projecting
filopodia, but spreading halted prematurely (27). Tat-CT
allowed more spreading of TNF-treated neutrophils than
wortmannin but less than tyrphostin A9, aborting their
projection of filopodia. It appears that Tat-CT blocked
TNF signaling in more ways, more completely, and/or at
an earlier step than tyrphostin A9. Mice deficient in p85 
subunit of PI3K die as embryos (58) and PI3K -deficient
mice displayed defects in thymocyte development, T cell
activation, and neutrophil migration (59–61). Genetic defi-
ciency of Syk (62, 63) led to perinatal lethality in mice. In
contrast, Pyk2-deficient mice appeared to be normal ex-
cept for impaired macrophage migration and a paucity of
marginal zone B cells (64).
Tat-CT blocked the bacteria-induced respiratory burst
but not the killing of Salmonella. This may seem paradoxical
insofar as Salmonella can cause life-threatening infections in
chronic granulomatous disease patients who lack the
phagocyte oxidase (phox; reference 65) and in mice that
are rendered phox-deficient through homologous recom-
bination (66). However, in some chronic granulomatous
disease patients with a regulatory rather than structural de-
fect in a gene encoding a phox subunit, restoration of phox
activity to 10% of normal by treatment with interferon- 
sufficed to endow their leukocytes with normal antibacte-
rial activity (67). In our studies, inhibition of the respiratory
burst by Tat-CT left the respiratory burst at  20% of nor-
mal, even though there appeared to be complete inhibition
of the phosphorylation of two of the tyrosine residues of
endogenous Pyk2. The combination of a small residual re-
spiratory burst with a normal level of degranulation may
account for the sparing of antibacterial activity in the pres-
ence of Tat-CT.
The tissue damaging potential of secreted reactive oxy-
gen intermediates and lysosomal proteases has been demon-
strated extensively (68–70). Critical for this discussion are
the synergistic interactions between these two sets of neu-
trophil secretory products. First, neutrophil-derived oxi-
dants contribute to the activation of latent neutrophil pro-
teases, such as collagenase and gelatinase (71, 72). Second,
neutrophil-derived oxidants can inactivate three of the ma-
jor tissue antiproteinases:  1 antiproteinase,  2-macroglob-
ulin, and secretory leukocyte protease inhibitor (69, 70, 73,
74). Thus, an intervention that markedly decreased the re-
spiratory burst of neutrophils responding to inflammatory
agonists might decrease tissue damage both directly and in-
directly. Selective regulation of the respiratory burst might
be an alternative to blocking all aspects of neutrophil acti-
vation, which would carry grave risk to host defense.
The cytochrome b558 components of phox (gp91 and
gp22) are localized primarily in the membranes of specific
granules in neutrophils (75) and assembly of the full oxidase
complex involves their recruitment to plasma or phagoso-
mal membranes (76). Thus, the activation of the respiratory
burst depends on degranulation. Tat-CT blocked the respi-
ratory burst but did not impair degranulation. It follows
that the COOH terminus of Pyk2 is likely to mediate some
aspect of phox assembly distal to the mobilization of gp91/
gp22, a step that can be bypassed when PMA activates pro-
tein kinase C. Possible loci of action for Pyk2 (directly or
indirectly) include the phosphorylation of phox47 and the
recruitment of the small GTPase components of the oxi-
dase complex.
The discovery that the neutrophil respiratory burst oxi-
dase can be substantially inhibited without blocking de-
granulation or bacterial killing in vitro directs attention to a
search for members of the Pyk2 pathway that might be
more myeloid-specific than Pyk2 itself. Such proteins
might be a suitable experimental target for antiinflamma-
tory therapy.
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